Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT03618550. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study of Second-line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.
Study identification
- NCT ID
- NCT03618550
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 257 participants
Conditions and interventions
Interventions
- pembrolizumab Drug
- gemcitabine Drug
- vinorelbine Drug
- liposomal doxorubicin Drug
- Stem cell mobilization and collection Procedure
- Involved-site radiation therapy Radiation
Drug · Procedure · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2018
- Primary completion
- Jul 31, 2027
- Completion
- Jul 31, 2027
- Last update posted
- Aug 6, 2026
2018 – 2027
United States locations
- U.S. sites
- 10
- U.S. states
- 4
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Cancer Center (Data Collection Only) | Duarte | California | 91010 | Not yet recruiting |
| Stanford University Medical Center | Stanford | California | 94305-5408 | Not yet recruiting |
| University of Miami | Miami | Florida | 33136 | Recruiting |
| Memorial Sloan Kettering Basking Ridge | Basking Ridge | New Jersey | 07920 | Recruiting |
| Memorial Sloan Kettering Monmouth | Middletown | New Jersey | 07748 | Recruiting |
| Memorial Sloan Kettering Bergen | Montvale | New Jersey | 07645 | Recruiting |
| Memorial Sloan Kettering Cancer Center @ Commack | Commack | New York | 11725 | Recruiting |
| Memorial Sloan Kettering Westchester | Harrison | New York | 10604 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| Memorial Sloan Kettering Nassau | Uniondale | New York | 11553 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03618550, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 6, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03618550 live on ClinicalTrials.gov.